Literature DB >> 23146688

The role of co-factors in the progression from human papillomavirus infection to cervical cancer.

Patricia Luhn1, Joan Walker, Mark Schiffman, Rosemary E Zuna, S Terence Dunn, Michael A Gold, Katherine Smith, Cara Mathews, Richard A Allen, Roy Zhang, Sophia Wang, Nicolas Wentzensen.   

Abstract

OBJECTIVE: Co-factors for cervical cancer, including oral contraceptive (OC) use, smoking and multiparity have been identified; however, the stage at which they act in cervical carcinogenesis is not clear. We compared established risk factors among women with CIN2 and CIN3 to evaluate the heterogeneity of these factors in precancer and also assessed their role during cervical carcinogenesis.
METHODS: The current analysis included 2783 women with various stages of cervical disease who were enrolled in the Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED) and the Biopsy Study. Associations of co-factors within cervical precancer and at different stages of cervical carcinogenesis were estimated using logistic regression.
RESULTS: Long-term OC use (10+years vs. never: OR=2.42, 95% CI: [1.13-5.15]), multiparity (3+ births vs. nulliparous: OR=1.54 [1.04-2.28]), smoking (ever vs. never: OR=1.95 [1.48-2.58]), and no Pap test in the previous five years (2.05 [1.32-3.17]) were positively associated with CIN3 compared to CIN2. We observed that long-term OC use, parity and smoking were associated with an increased risk of CIN3 compared to <CIN2 (1.97 [1.12-3.46]; 2.23 [1.59-3.11]; 2.60 [2.04-3.30], respectively), whereas associations were not significantly different (OC use, parity) or showed decreased risk (smoking) when comparing cancer to CIN3.
CONCLUSIONS: Differences in established risk factors suggest that CIN3 is a more specific definition of precancer than CIN2. Hormonally-related factors and smoking play a role in the transition from human papillomavirus infection to precancer. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23146688      PMCID: PMC4627848          DOI: 10.1016/j.ygyno.2012.11.003

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  29 in total

Review 1.  Estrogen and ERalpha: culprits in cervical cancer?

Authors:  Sang-Hyuk Chung; Silvia Franceschi; Paul F Lambert
Journal:  Trends Endocrinol Metab       Date:  2010-04-22       Impact factor: 12.015

Review 2.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

3.  Co-factors of high-risk human papillomavirus infections display unique profiles in incident CIN1, CIN2 and CIN3.

Authors:  K Syrjänen; I Shabalova; P Naud; S Derchain; L Sarian; V Kozachenko; S Zakharchenko; C Roteli-Martins; R Nerovjna; A Longatto-Filho; L Kljukina; S Tatti; M Branovskaja; M Branca; V Grunjberga; M Erzen; A Juschenko; L Serpa Hammes; S Costa; J Podistov; S Syrjänen
Journal:  Int J STD AIDS       Date:  2011-05       Impact factor: 1.359

4.  The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report.

Authors:  Philip E Castle; Mark H Stoler; Diane Solomon; Mark Schiffman
Journal:  Am J Clin Pathol       Date:  2007-05       Impact factor: 2.493

5.  CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples.

Authors:  Joseph D Carreon; Mark E Sherman; Diego Guillén; Diane Solomon; Rolando Herrero; Jose Jerónimo; Sholom Wacholder; Ana Cecilia Rodríguez; Jorge Morales; Martha Hutchinson; Robert D Burk; Mark Schiffman
Journal:  Int J Gynecol Pathol       Date:  2007-10       Impact factor: 2.762

6.  Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants.

Authors:  Sophia S Wang; Rosemary E Zuna; Nicolas Wentzensen; S Terence Dunn; Mark E Sherman; Michael A Gold; Mark Schiffman; Sholom Wacholder; Richard A Allen; Ingrid Block; Kim Downing; Jose Jeronimo; J Daniel Carreon; Mahboobeh Safaeian; David Brown; Joan L Walker
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

7.  Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants.

Authors:  Nicolas Wentzensen; Mark Schiffman; Terence Dunn; Rosemary E Zuna; Michael A Gold; Richard A Allen; Roy Zhang; Mark E Sherman; Sholom Wacholder; Joan Walker; Sophia S Wang
Journal:  Int J Cancer       Date:  2009-11-01       Impact factor: 7.396

8.  Expression of an endogenous retroviral sequence from the HERV-H group in gastrointestinal cancers.

Authors:  Nicolas Wentzensen; Johannes F Coy; Hanns-Peter Knaebel; Michael Linnebacher; Birgit Wilz; Johannes Gebert; Magnus von Knebel Doeberitz
Journal:  Int J Cancer       Date:  2007-10-01       Impact factor: 7.396

9.  Clinical and pathological heterogeneity of cervical intraepithelial neoplasia grade 3.

Authors:  Hannah P Yang; Rosemary E Zuna; Mark Schiffman; Joan L Walker; Mark E Sherman; Lisa M Landrum; Katherine Moxley; Michael A Gold; S Terence Dunn; Richard A Allen; Roy Zhang; Rodney Long; Sophia S Wang; Nicolas Wentzensen
Journal:  PLoS One       Date:  2012-01-13       Impact factor: 3.240

10.  Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.

Authors:  Cosette M Wheeler; William C Hunt; Nancy E Joste; Charles R Key; Wim G V Quint; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

View more
  36 in total

Review 1.  Human papillomavirus genome variants.

Authors:  Robert D Burk; Ariana Harari; Zigui Chen
Journal:  Virology       Date:  2013-08-31       Impact factor: 3.616

2.  [Epidemiology, prevention and early detection of cervical cancer].

Authors:  Nicolas Wentzensen
Journal:  Onkologe (Berl)       Date:  2016-08-04       Impact factor: 0.234

3.  Association between interleukin-2, interleukin-10, secretory immunoglobulin A and immunoglobulin G expression in vaginal fluid and human papilloma virus outcome in patients with cervical lesions.

Authors:  Jing-Wei Meng; Jing-Hui Song
Journal:  Oncol Lett       Date:  2019-09-20       Impact factor: 2.967

4.  Smoking cessation advice after cervical screening: a qualitative interview study of acceptability in Dutch primary care.

Authors:  Marthe Bl Mansour; Mathilde R Crone; Henk C van Weert; Niels H Chavannes; Kristel M van Asselt
Journal:  Br J Gen Pract       Date:  2018-12-03       Impact factor: 5.386

5.  Recurrence of cervical cancer in mice after selective estrogen receptor modulator therapy.

Authors:  Megan E Spurgeon; Sang-Hyuk Chung; Paul F Lambert
Journal:  Am J Pathol       Date:  2014-02       Impact factor: 4.307

Review 6.  Human papillomavirus infection and the multistage carcinogenesis of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

7.  A prospective cohort study of oral contraceptive use and ovarian cancer among women in the United States born from 1947 to 1964.

Authors:  Amy L Shafrir; Helena Schock; Elizabeth M Poole; Kathryn L Terry; Rulla M Tamimi; Susan E Hankinson; Bernard A Rosner; Shelley S Tworoger
Journal:  Cancer Causes Control       Date:  2017-03-13       Impact factor: 2.506

Review 8.  Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.

Authors:  Jennifer A Doherty; Allan Jensen; Linda E Kelemen; Celeste L Pearce; Elizabeth Poole; Joellen M Schildkraut; Kathryn L Terry; Shelley S Tworoger; Penelope M Webb; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2017-10-01       Impact factor: 13.506

9.  Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling.

Authors:  Johan A den Boon; Dohun Pyeon; Sophia S Wang; Mark Horswill; Mark Schiffman; Mark Sherman; Rosemary E Zuna; Zhishi Wang; Stephen M Hewitt; Rachel Pearson; Meghan Schott; Lisa Chung; Qiuling He; Paul Lambert; Joan Walker; Michael A Newton; Nicolas Wentzensen; Paul Ahlquist
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-08       Impact factor: 11.205

10.  Human papillomavirus oncogenes reprogram the cervical cancer microenvironment independently of and synergistically with estrogen.

Authors:  Megan E Spurgeon; Johan A den Boon; Mark Horswill; Sonalee Barthakur; Omid Forouzan; Janet S Rader; David J Beebe; Avtar Roopra; Paul Ahlquist; Paul F Lambert
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.